Nevro (NVRO) Revenue & Revenue Breakdown
Nevro Revenue Highlights
Latest Revenue (Y)
$425.17M
Latest Revenue (Q)
$101.90M
Main Segment (Y)
Painful Diabetic Neuropathy
Main Geography (Y)
UNITED STATES
Nevro Revenue by Period
Nevro Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $425.17M | 4.63% |
| 2022-12-31 | $406.37M | 5.03% |
| 2021-12-31 | $386.90M | 6.87% |
| 2020-12-31 | $362.05M | -7.23% |
| 2019-12-31 | $390.25M | 0.77% |
| 2018-12-31 | $387.29M | 18.56% |
| 2017-12-31 | $326.67M | 42.96% |
| 2016-12-31 | $228.50M | 228.28% |
| 2015-12-31 | $69.61M | 113.69% |
| 2014-12-31 | $32.57M | 38.61% |
| 2013-12-31 | $23.50M | 29.48% |
| 2012-12-31 | $18.15M | - |
Nevro generated $425.17M in revenue during NA 2023, up 4.63% compared to the previous quarter, and up 109.78% compared to the same period a year ago.
Nevro Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $101.90M | -12.29% |
| 2023-12-31 | $116.18M | 11.86% |
| 2023-09-30 | $103.86M | -4.55% |
| 2023-06-30 | $108.81M | 12.96% |
| 2023-03-31 | $96.33M | -15.39% |
| 2022-12-31 | $113.84M | 13.32% |
| 2022-09-30 | $100.47M | -3.60% |
| 2022-06-30 | $104.21M | 18.64% |
| 2022-03-31 | $87.84M | -14.52% |
| 2021-12-31 | $102.76M | 10.25% |
| 2021-09-30 | $93.20M | -8.92% |
| 2021-06-30 | $102.33M | 15.48% |
| 2021-03-31 | $88.61M | -19.25% |
| 2020-12-31 | $109.73M | 1.17% |
| 2020-09-30 | $108.46M | 92.34% |
| 2020-06-30 | $56.39M | -35.53% |
| 2020-03-31 | $87.47M | -23.53% |
| 2019-12-31 | $114.37M | 14.19% |
| 2019-09-30 | $100.16M | 7.04% |
| 2019-06-30 | $93.57M | 13.91% |
| 2019-03-31 | $82.15M | -23.90% |
| 2018-12-31 | $107.94M | 12.88% |
| 2018-09-30 | $95.63M | -0.47% |
| 2018-06-30 | $96.08M | 9.64% |
| 2018-03-31 | $87.64M | -10.54% |
| 2017-12-31 | $97.96M | 19.10% |
| 2017-09-30 | $82.26M | 5.43% |
| 2017-06-30 | $78.02M | 13.99% |
| 2017-03-31 | $68.44M | -2.97% |
| 2016-12-31 | $70.53M | 15.77% |
| 2016-09-30 | $60.92M | 9.97% |
| 2016-06-30 | $55.40M | 33.01% |
| 2016-03-31 | $41.65M | 25.74% |
| 2015-12-31 | $33.12M | 115.06% |
| 2015-09-30 | $15.40M | 34.89% |
| 2015-06-30 | $11.42M | 18.17% |
| 2015-03-31 | $9.66M | -0.55% |
| 2014-12-31 | $9.71M | 12.08% |
| 2014-09-30 | $8.67M | 15.17% |
| 2014-06-30 | $7.53M | 12.94% |
| 2014-03-31 | $6.66M | 7.55% |
| 2013-12-31 | $6.20M | -0.03% |
| 2013-09-30 | $6.20M | - |
Nevro generated $101.90M in revenue during Q1 2024, up -12.29% compared to the previous quarter, and up 89.51% compared to the same period a year ago.
Nevro Revenue Breakdown
Nevro Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Painful Diabetic Neuropathy | $77.90M | $48.00M | $5.70M |
Nevro's latest annual revenue breakdown by segment (product or service), as of Dec 23: Painful Diabetic Neuropathy (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|
| Painful Diabetic Neuropathy | $22.50M | $20.80M | $19.00M | $15.60M | $17.60M | $13.40M | $11.00M | $6.00M | $1.70M |
Nevro's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Painful Diabetic Neuropathy (100.00%).
Nevro Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| UNITED STATES | $366.56M | $348.17M | $326.22M | $311.87M | $326.01M |
| Non-US | $58.62M | $58.20M | - | - | - |
| Non Us | - | - | $60.69M | $50.17M | $64.24M |
Nevro's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (86.21%), and Non-US (13.79%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $14.86M | $14.66M | $14.10M | $15.85M | $14.01M | $14.07M | $14.34M | $15.16M | - | - | - | - | - |
| UNITED STATES | $87.04M | $101.52M | $89.76M | $92.96M | $82.32M | $99.77M | $86.13M | $89.05M | $73.21M | $91.62M | $79.62M | $79.91M | $70.62M |
| Non Us | - | - | - | - | - | - | - | - | $14.63M | $16.32M | $16.01M | $16.17M | $17.01M |
Nevro's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (85.42%), and Non-US (14.58%).
Nevro Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ITGR | Integer | $1.60B | $746.27M |
| CNMD | CONMED | $1.24B | $316.70M |
| LIVN | LivaNova | $1.15B | $318.11M |
| NVRO | Nevro | $425.17M | $101.90M |
| GKOS | Glaukos | $314.71M | $95.69M |
| FNA | Paragon 28 | $216.39M | $61.02M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SRDX | Surmodics | $132.58M | $30.34M |
| RXST | RxSight | $89.08M | $45.52M |
| SGHT | Sight Sciences | $81.06M | $21.37M |
| LUNG | Pulmonx | $68.67M | $20.39M |
| IRMD | IRadimed | $65.56M | $18.33M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| CVRX | CVRx | $39.30M | $13.37M |
| OSA | ProSomnus | $27.65M | $7.46M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
NVRO Revenue FAQ
What is Nevro’s yearly revenue?
Nevro's yearly revenue for 2023 was $425.17M, representing an increase of 4.63% compared to 2022. The company's yearly revenue for 2022 was $406.36M, representing an increase of 5.03% compared to 2021. NVRO's yearly revenue for 2021 was $386.9M, representing an increase of 6.87% compared to 2020.
What is Nevro’s quarterly revenue?
Nevro's quarterly revenue for Q1 2024 was $101.9M, a -12.29% decrease from the previous quarter (Q4 2023), and a 5.78% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $116.18M, a 11.86% increase from the previous quarter (Q3 2023), and a 2.05% increase year-over-year (Q4 2022). NVRO's quarterly revenue for Q3 2023 was $103.86M, a -4.55% decrease from the previous quarter (Q2 2023), and a 3.38% increase year-over-year (Q3 2022).
What is Nevro’s revenue growth rate?
Nevro's revenue growth rate for the last 3 years (2021-2023) was 9.89%, and for the last 5 years (2019-2023) was 8.95%.
What are Nevro’s revenue streams?
Nevro's revenue streams in c 23 are Painful Diabetic Neuropathy
What is Nevro’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Nevro was Painful Diabetic Neuropathy. This segment made a revenue of $77.9M, representing 100.00% of the company's total revenue.